BioPharma Clinical Trials

TiumBio Advances TU2218 in Phase 2a Trial with Pembrolizumab for Three Cancer Types

TiumBio will pursue three indications for the TU2218 combination clinical trial with pembrolizumab TU2218 demonstrated a favorable safety and a synerget...

 March 12, 2024 | News

ImmunAbs Announces Triumph in Phase 1 Clinical Trial of Novel Autoimmune Disease Therapy, IM-101

ImmunAbs, a leading clinical-stage biotechnology company focused on developing novel antibody therapeutics, today announced the successful completion of th...

 March 12, 2024 | News

Eli Lilly Reveals Promising Phase 3 Results for Lebrikizumab in Patients with Skin of Color

Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color...

 March 11, 2024 | News

TransThera Launches Global Phase 3 Trial for Cholangiocarcinoma in EU, Receives Orphan Drug Status for Tinengotinib from EMA

TransThera, a clinical-stage biopharmaceutical company dedicated to innovating differentiated drugs globally, today announced that the randomized, controll...

 March 11, 2024 | News

First Patient Treated in Phase 2 GvHD Trial

Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, c...

 March 06, 2024 | News

Caliway's CBL-514 Gains FDA Orphan Drug and Fast Track Designations for Dercum's Disease Treatment

Caliway Biopharmaceuticals (Caliway) announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to CBL-514 for Dercum...

 March 05, 2024 | News

SN Bioscience's SNB-101 Granted FDA Orphan Drug Designation for Pancreatic Cancer Treatment

SN Bioscience Co. Ltd. (CEO Park Young-hwan) announced on Feb 27 that the US FDA had granted an orphan drug designation for pancreatic cance...

 March 01, 2024 | News

Innovent Begins Phase 1 Trial of IBI3002 in Australia

  This FIH study (NCT06213844) is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study to evaluate the safety, tolerabil...

 March 01, 2024 | News

Medidata and Sanofi Boost Trial Efficiency with Expanded Patient-Centric Collaboration

 Medidata, a Dassault Systèmes subsidiary and a leading provider of clinical trial solutions for the life sciences industry, today announced a ...

 February 29, 2024 | News

Teva Partners with Jiangsu Nhwa to Enhance AUSTEDO® Access in China

  “Nhwa has deep neuro-psychiatry expertise and capabilities, from research and development to commercialization,” commented Theodor Wee,...

 February 28, 2024 | News

Neomorph, Novo Nordisk Partner on Molecular Glue Degraders for Diseases

Collaboration leverages Neomorph's leading molecular glue discovery platform and Novo Nordisk's extensive expertise in cardiometabolic and rare diseases ...

 March 27, 2024 | News

Everest Medicines, Kezar Get China NMPA Nod for Lupus Nephritis Trial

Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced that the Center for Drug Evaluation (CDE) of China's Natio...

 February 27, 2024 | News

Oscotec/ ADEL Launch First Human Trial for Novel Alzheimer's Treatment ADEL-Y01

  In a significant stride towards Alzheimer's disease (AD) treatment, Oscotec Inc. in collaboration with ADEL Inc., has announced the initiation of f...

 February 26, 2024 | News

Immunofoco Achieves Historic Dual IND Approval for Groundbreaking EpCAM CAR-T Therapy

  EpCAM, known for its presence in circulating tumor cells (CTCs) and high expression in primary and metastatic lesions of gastrointestinal tumors, r...

 February 26, 2024 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close